STOCK TITAN
  1. Home
  2. News
  3. OPT

Opthea Limited - OPT STOCK NEWS

Welcome to our dedicated news page for Opthea (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opthea's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opthea's position in the market.

News
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Rhea-AI Summary
Opthea appoints Dr. John Han as Vice President of Medical Affairs, bringing extensive experience in retinal and ophthalmology diseases. Dr. Han's track record in medical affairs and launching therapies for patients with retinal disease will support Opthea's Phase 3 trial for wet AMD drug, sozinibercept.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
management
-
News
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 
Rhea-AI Summary
Opthea to Present at 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
-
News
Opthea Appoints Sujal Shah to the Board of Directors
Rhea-AI Summary
Opthea appoints Sujal Shah, a former CymaBay Therapeutics CEO, as Non-Executive Director and Audit and Risk Committee Chair. Shah's extensive biopharmaceutical leadership experience adds value to Opthea's Board as they advance therapies for retinal diseases like wet AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
management
News
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
Rhea-AI Summary
Opthea (ASX:OPT; NASDAQ:OPT) to host a virtual KOL event focusing on sozinibercept's potential in treating wet AMD. The event will feature global retina experts discussing Phase 2b data and ongoing Phase 3 trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Opthea to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Opthea Limited to participate in investor meetings at Leerink Partners Global Biopharma Conference in Miami, Florida. Opthea is a clinical-stage biopharmaceutical company focusing on retinal disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
conferences
-
News
Opthea Reports Half-Year Financial Results and Business Updates
Rhea-AI Summary
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced the completion of enrollment in the Phase 3 program for sozinibercept by Q2 2024, with top-line data expected in mid-2025. The company also expanded its U.S. leadership team and reported cash and cash equivalents of $157.1 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
earnings
News
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Rhea-AI Summary
Opthea Limited appoints Dr. Arshad M. Khanani as Chief Medical Advisor to support the development of sozinibercept, a potential breakthrough treatment for wet age-related macular degeneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
management
-
News
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
Rhea-AI Summary
Opthea Limited completes enrollment of patients in COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept for the treatment of wet AMD. ShORe trial enrollment to be completed in Q2 2024 with top-line results expected by mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
News
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Rhea-AI Summary
Opthea Limited announced the appointment of Dr. Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Dr. Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs. Both bring extensive experience in products for retinal and ophthalmology diseases. Dr. Clark and Dr. Li will report to Opthea CEO Frederic Guerard and will join the Opthea Executive Management Team. The company is preparing for the next stage in its growth and working towards advancing the development of sozinibercept (OPT-302), currently in two Phase 3 pivotal trials. Dr. Clark and Dr. Li expressed excitement to contribute to the potential success of the lead program investigating sozinibercept and to bring this novel product candidate to patients with serious retinal disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
management
News
Opthea to Receive US$35M Commitment and Additional US$50M Funding
Rhea-AI Summary
Opthea Limited (ASX:OPT; NASDAQ:OPT) to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor. The financing is non-dilutive to shareholders, with no equity issued to Carlyle, Abingworth, or the new co-investor. This investment is driven by the potential of sozinibercept (OPT-302) to provide superior visual outcomes for wet AMD patients and to provide a multi-billion dollar commercial opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.65%
Tags
none
Stock OPT logo
Opthea Limited

Nasdaq:OPT

OPT Rankings

#3452 Ranked by Market Cap
#5052 Ranked by Stock Gains
N/A Ranked by Dividends

OPT Stock Data

314.83M
480.83M
9.46%
0.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Australia
Melbourne

About OPT

opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com